References
- AltahaRCrowellEDucatmanB2004Risk of brain metastases in HER2/neu-positive breast cancerJ Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition)22682
- American Cancer Society2007Cancer Facts and Figures 2006 [online]Accessed 21 June 2007 URL: http://www.cancer.org/docroots/STT/content/STT_1x_Cancer_Facts_Figures_2006.asp
- BlackwellKLBursteinHPegramM2005Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancerJ Clin Oncol23193s Abstract 3004. [Updated based on presentation.]
- BursteinHStornioloAMFrancoS2004A phase II, open-label, multicenter study of lapatinib in two cohorts of patients with advanced or metastatic breast cancer who have progressed while receiving trastuzumab-containing regimensAnn Oncol15suppl 327 (abstract 104O)
- CameronDMartinA-MNewstatB2007Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): updated efficacy and biomarker analysisJ Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I251035
- ClaytonAJDansonSJollyS2004Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancerBr J Cancer916394315266327
- ESMO Guidelines Working Group2007Recurrent or metastatic breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-upAnn Oncol18Suppl 2ii9ii1117491064
- GeyerCEForsterJLindquistD2006Lapatinib plus capecitabine for HER2-positive advanced breast cancerN Engl J Med35527334317192538
- GomezHLChavezMADovalDCResults from a phase II randomized study of lapatinib as first-line treatment for patients with HER2-amplified locally advanced or metastatic breast cancerPoster presentation at the 29th Annual San Antonio Breast Cancer Symposium2006 Abstract 1090. available at:http://www.posters2view.com/sabcs06/view.php?nu=1090Accessed June 19, 2007
- HeimannRHellmanS2000Clinical progression of breast cancer malignant behavior: what to expect and when to expect itJ Clin Oncol18591910653874
- HortobagyiGN2005Continuation of trastuzumab beyond disease progression (letter to the editor)J Clin Oncol2328689
- KonecnyGEPegramMDVenkatesanN2006Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cellsCancer Res661630916452222
- LinNUDierasVPaulD2007Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancerJ Clin Oncol, ASCO Annual Meeting Proceedings Part I251012
- MontemurroFDonadioMClavarezzaM2006Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapyThe Oncologist113182416614227
- National Comprehensive Cancer Network2007NCCN clinical practice guidelines in oncology: Breast Cancer v.2.2007 [online]Accessed 21 June 2007 URL: http://www.nccn.org
- PerezEAByrneJAHammondIW2006Cardiac safety experience in 3127 patients (pts) treated with lapatinibAnn Oncol17suppl 8ix70
- RusnakDWLackeyKAffleckK2001The effects of the novel, reversible epidermal growth factor receptor/ERbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivoMol Cancer Therap1859412467226
- SchwartzGChuQS-CHammondLA2004Phase I clinical, biology and pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors (abstract 3070)J Clin Oncol2214S
- SeidmanADHudisCPierriMK2002Cardiac dysfunction in the trastuzumab clinical trials experienceJ Clin Oncol2012152111870163
- SlamonDJClarkGMWongSG1987Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogeneScience235177823798106
- StemmlerJSchmittMWillemsA2006Brain metastases in HER2-overexpressing metastatic breast cancer: comparative analysis of trastuzumab levels in serum and cerebrospinal fluid (abstract)J Clin Oncol, 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition)241525
- Tykerb (lapatinib) tablets2007Product informationResearch Triangle Park, NCGlaxoSmithKline